| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 8.24 | 0.01 (+0.18%) | 6.18 - 8.43 | 1.1 million (Below Avg) |
Market data as of 2:38PM 05/20/13. Quotes are delayed by at least 15 min.
| Open | 8.22 |
|---|---|
| Previous Close | 8.22 |
| Day's Range | 8.20 - 8.29 |
| Market Cap | 1.2B |
| Avg Volume (10 Day) | 1.9M |
| Price/Earnings (Trailing 12 Mo.) | 5.2x |
| Earnings Per Share (Trailing 12 Mo.) | 1.57 |
| Dividend Yield | 0.15 (7.29%) |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Pass |
| Increased earnings over time? | Pass |
| Borrows within reasonable limits? | Neutral |
| Stock is undervalued? | Pass |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Pass |
| Has sufficient liquidity? | Pass |
PDL BioPharma Announces First Quarter 2013 Financial Results
PR Newswire - Thursday 05/09/2013 4:02 PM ET
PDL BioPharma to Announce First Quarter 2013 Financial Results on May 9, 2013
PR Newswire - Thursday 05/02/2013 7:00 AM ET
PDL BioPharma Appoints Peter Garcia as Chief Financial Officer
PR Newswire - Tuesday 04/30/2013 4:02 PM ET
PDL BioPharma Completes Structured Financing and Royalty Transaction with Avinger
PR Newswire - Monday 04/22/2013 12:50 PM ET
Avinger Completes Mezzanine Financing with PDL Biopharma
Business Wire - Monday 04/22/2013 7:00 AM ET
| PDLI | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 9.26% | |
| Net Income Growth (1yr) | 15.35% | |
| Total Debt/Equity | -- | |
| LT Debt/Equity | -- | |
| Earnings Yield | 19.23% | |
| Price/Sales | 2.96 |
| Company | Last | Change |
|---|---|---|
| Ambit Biosciences Corp | 6.78 | +0.44% |
| Lexicon Pharmaceuticals Inc | 2.19 | -1.13% |
| TESARO Inc | 35.31 | -1.67% |
| Nektar Therapeutics | 9.76 | -0.31% |
| Sarepta Therapeutics Inc | 37.42 | +1.38% |
Data is delayed by at least 15 min.